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Abstract 
 
Introduction 
Genetic abnormalities play an integral role in the pathogenesis, diagnosis, prognosis and 
treatment of leukaemia. As the technology advances in the field of molecular testing, so will our 
approach to the diagnosis and treatment of patients presenting with suspected leukaemia. Our 
aim was to evaluate the Signature® LTx Multiplex RT-PCR assay which combines multiplex RT-PCR 
(Reverse Transcription Polymerase Chain Reaction) with multiplex fluorescent bead-array 
detection and to compare results with those of routine diagnostic tests FISH (Fluorescent In Situ 
Hybridisation) and cytogenetics analysis. The assay has 12 translocations commonly associated 
with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) and chronic myeloid 
leukaemia (CML).  
Material and Methods 
RNA was extracted from bone marrow aspirate and peripheral blood samples from both adult 
and paediatric patients presenting with ALL, AML and CML and analysed 70 samples using the 
multiplex assay with four steps of reverse transcription, DNA amplification, hybridisation and 
detection. Qualitative analysis was performed with a pre-determined mean fluorescence intensity 
(MFI) cut off level as well as quantitative analysis of signal distributions for positive, negative and 
endogenous controls (GAPDH: glyceraldehyde 3-phosphate dehydrogenase). Results were then 
compared to those of cytogenetics and FISH.  
Results 
Eighty six percent of the samples had concordant results and 14% showed discordant results 
compared to routine diagnostic tests. Of these discordant samples, some results could be 
explained by suboptimal RNA quantity or GAPDH MFI signals and if these were repeated or 
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discarded, the number of discordant samples would decrease to four percent. The multiplex 
detected four translocations which were not identified by FISH or cytogenetics and 6 mutations 
were missed by the assay, however the majority of these are attributable to suboptimal RNA and 
internal control signals which would be repeated in the routine use of the assay.  
Conclusion 
Overall, the Signature® LTX Multiplex RT-PCR assay showed good correlation with gold standard 
test techniques. While the assay provides possible advantages including ease of use and improved 
turnaround times, drawbacks include problems with RNA quantity after extraction and logistical 
concerns including the need to batch samples for analysis which will affect the turnaround time. 
Careful cost analysis and possible modification of the translocations included in the assay would 
be required before the assay could be incorporated as part of the routine diagnostic work-up of 
patients presenting with leukaemia.  
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1) Introduction 
1.1 Leukaemia 
Leukaemia comprises a diverse group of diseases characterised by abnormal proliferation and 
development of leukocyte precursors and subsequent bone marrow infiltration and failure [1]. 
The different subtypes include chronic and acute leukaemia affecting both myeloid and lymphoid 
lineages. Aetiology may be complex with both genetic and environmental contributors including 
congenital syndromes linked to predisposition to malignancy. Morphology, cytochemistry and 
immunophenotypic analysis are all crucial in the diagnosis and categorisation of these varied 
subtypes, but there has been an increasing emphasis on the molecular pathogenesis of the 
disease, not only to understand the aetiology and prognosis but to tailor treatment according to 
the underlying genetic lesion. Some categories of acute myeloid leukaemia (AML) for example are 
designated as an acute leukaemia according to the specific recurrent genetic abnormality, 
regardless of whether or not the required 20 % blast count is met [2]. As the technology advances 
in the field of molecular testing, so will our approach to the diagnosis and treatment of patients 
presenting with suspected leukaemia. For the purposes of this research report, the focus will be 
on the acute leukaemias (myeloid and lymphoid) as well as chronic myeloid leukaemia (CML).  
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1.2 Leukaemia statistics 
According to the South African Paediatric Tumour Registry, leukaemia is the most common 
childhood cancer, accounting for 25.4% of all cancers.  The annual incidence of all tumours in 
children aged 0-14 years living in South Africa over the period 2003-2007 ranged from 33.4 to 
47.2 per million [3]. The National Cancer Registry (NCR) established by the National Health 
Laboratory Service (NHLS) in 1986 serves an important epidemiological function by keeping a 
record of all the diagnoses of malignancies made. It is a pathology-based registry and relies on 
tissue diagnosis and accurate reporting by pathologists. The 2008 annual report states that 
leukaemia comprised 1.47 % of all cancers in adult males with an age-standardised incidence rate 
of 1.32 per 100 000 and 1.08 % of all cancers in adult females with age-standardised incidence 
rate of 2.03 per 100 000 [4].  
According to the NCR data collected from 2000-2005 at Chris Hani Baragwanath Academic 
Hospital (CHBAH) and Charlotte Maxeke Johannesburg Academic Hospital (CMJAH),  a total of 203 
cases of Acute Lymphoblastic Leukaemia (ALL), 26 cases of acute promyelocytic leukaemia (APL), 
96 cases of CML and 179 cases of AML were reported.  
In order to confirm and update these figures at our centre, data was collected from the Flow 
Cytometry Register over the period of 18 months starting January 2012 at CMJAH. Samples from 
CHBAH, Donald Gordon Medical Centre (DGMC), Helen Joseph Hospital (HJH) and peripheral 
hospitals are sent to CMJAH for immunophenotypic analysis, therefore the numbers are 
considered an adequate representation of our referral population, including even more centres 
than the NCR statistics which is reflected in the increased numbers of all the above malignancies 
based on the Flow Cytometry data. In this time period, 54 cases of B-ALL and 30 cases of T-ALL 
were diagnosed. CML comprised 55 of new leukaemia samples with AML and APL accounting for 
94 and 32 of all new cases respectively. If an ambiguous lineage leukaemia was suspected or the 
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sample was inadequate for complete assessment, but the overall blast percentage was greater 
than 20%, the samples were characterised as Acute Leukaemia (n = 11). These figures are 
represented in Figure 1 below. 
 
Figure 1.1: New leukaemia cases according to immunophenotypic data at CMJAH from January 
2012 until July 2013. 
 
1.3 Diagnosis 
Current World Health Orginisation (WHO) diagnostic criteria in leukaemia require the use of a 
multifaceted approach.   This incorporates the use of morphological, cytochemical, 
immunophenotypic as well as cytogenetic and molecular analysis [2]. Of the detection methods 
available, genetic studies provide the most important information with regard to diagnosis, risk 
stratification and therapeutic strategies. The 2008 WHO classification emphasises the importance 
of this genetic information by using specific balanced translocations as the basis for a large 
proportion of its leukaemia classification system, which will be discussed in more detail for the 
purposes of this study [2].    
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1.3.1 Acute myeloid leukaemia 
AML is a defined by clonal expansion of myeloid blasts in the peripheral blood, bone marrow or 
other tissues [2]. It includes a wide range of clinical, morphological and genetic features. The 
different categories are shown in Table 1.1. With regards to leukaemogenesis, two groups of 
mutations have been defined i.e. class I and class II mutations. Class I mutations cause 
proliferation and increased survival of leukaemic cells by activation of signal transduction 
pathways, whereas class II mutations cause impaired differentiation by affecting components of 
transcription factors[5]. Class II mutations include the Core Binding Factor leukaemias AML with 
t(8;21)(q22;q22); RUNX1-RUNX1T1 and AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); 
CBFB-MYH11. 
Table 1.1: Categories of AML according to WHO 2008 classification[2] 
AML with recurrent genetic abnormalities: 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARa 
AML with t(9;22)(p22;g23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional AML with mutated NPM1 
Provisional AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML, not otherwise specified (NOS) 
Myeloid sarcoma 
Myeloid proliferations related to Down Syndrome 
Blastic plasmacytoid dendritic cell neoplasms 
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In AML, the core binding factor complex mutations, inv (16)(p13.1q22);CBFB-MYH11 and                      
t(8;21)(q22:q22);RUNX1-RUNX1T1are diagnostic of AML irrespective of blast count and are 
associated with higher rates of complete remission and a lower risk of relapse [6]. The t(8;21) 
mutation is found in approximately 5% of AML and inv(16) in 5-8% of cases [2]. These two 
mutations fall under the category of Acute Myeloid Leukaemia with recurrent genetic 
abnormalities and both affect subunits of the core binding factor complex, a transcription factor 
complex essential for regulation of haemopoiesis particularly myeloid differentiation[7]. The 
t(8;21)(q22:q22);RUNX1-RUNX1T1mutation involves the RUNX1 (runt-related transcription factor 
1) gene encoding CBFA (core-binding factor subunit alpha) and RUNX1T1 (ETO)(runt-related 
transcription factor 1; translocated to, 1) gene. This results in impaired haemopoietic 
differentiation since RUNX1T1 (ETO) associates with N-Cor (nuclear receptor co-repressor) and 
blocks transcription of target genes [8]. This translocation is often associated with French 
American British (FAB) classification AML M2 (acute myeloid leukaemia with differentiation) and 
is commonly found in younger patients (median 36 years) [2, 9, 10]. 
 
The inv (16)(p13.1q22);CBFB-MYH11[or t(16;16)(p13.1;q22)] mutation fuses the CBFB gene 
(encoding core binding factor beta subunit) at 16q22 to the MYH11 gene at 16p13.1. MYH11 
which codes for smooth muscle myosin heavy chain. The fusion protein also associates with co-
repressor complexes and leads to subsequent differentiation arrest [11, 12]. It is a cryptic 
translocation and may be missed on conventional cytogenetics therefore Fluorescent In Situ 
Hybridisation (FISH) analysis or Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
methods are recommended to detect this mutation [13]. It is commonly identified in AML M4 Eo 
subtypes with characteristic eosinophil component and can be found in all age groups, but 
predominantly younger patients (median 41 years) [2, 14]. 
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APL or AML with t(15;17)(q22;q12); PML-RARa accounts for 5-8 % of AML cases and can occur at 
any age, predominantly adults. The translocation involves the fusion of the retinoic acid receptor 
alpha (RARa) gene on 17q12 to a nuclear regulatory gene PML (promyelocytic leukaemia) on 
15q22, however in the minority of cases (<5%) other translocations involving fusion partners 
other than the PML gene are identified [15]. There are three PML-RARa transcript subtypes 
depending on the location of the breakpoints in the PML region - bcr1, bcr2 and bcr3 (breakpoint 
cluster region). Bcr3 is known as the short (S) isoform and bcr1 and bcr2 together constitute the 
long (L) isoform [16].The abnormal PML-RARa fusion protein, through various targets of action, 
results in transcriptional repression of retinoic acid signalling [17]. Identifying this translocation 
allows for molecularly targeted therapy all-trans retinoic acid (ATRA) and therefore confers a 
favourable prognosis [2].  APL is considered a haematological emergency and treatment should 
be started as soon as possible, highlighting the need for a molecular testing technique with a 
rapid turnaround time (TAT).  
1.3.2 Chronic myeloid leukaemia 
 
Chronic Myeloid Leukaemia is characterised by t(9;22)(q34;q11.2);BCR-ABL1, also known as the 
Philadelphia chromosome . The translocation fuses BCR (breakpoint cluster region) at 22q11.2 
and ABL1 (Abelson murine leukaemia viral oncogene homolog 1), a cytoplasmic tyrosine kinase 
gene at 9q43. The resultant oncogene encodes a protein with constitutive activity of the kinase 
[18]. In most patients with CML and in approximately one third of patients with Philadelphia-
positive (Ph+) B-cell ALL, the breakpoint within BCR is the major breakpoint cluster region (M-bcr) 
resulting in a 210-kDa (kilo-Dalton) protein (p210 BCR-ABL1) by either b2a2 or b3a2 splicing (refer 
Figure 1.2). In two thirds of patients with Ph+ B-ALL and rare cases of CML, the minor breakpoint 
cluster region (m-bcr) is between exons e1 and e2 and a p190 BCR-ABL fusion protein is 
translated from the e1a2 transcript as shown in Figure 1.2 [18]. The detection of t(9; 22) BCR-
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ABL1 allows for the selection of specific tyrosine kinase inhibitors e.g. Imatinib as treatment 
which has significantly improved outcomes of patients with CML [19].  
 
              Ib               Ia         a2    a3                                                       a11 
 
 
 
                                                                    b2       b3 
 
 
 
 
 
 
 
 
 
Figure 1.2 Breakpoint locations in ABL and BCR genes in chronic myeloid leukaemia (adapted 
from [20]) 
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1.3.3 Acute lymphoblastic leukaemia 
 
ALL affects mostly children with 75% of cases under the age of six years [2]. ALL is a neoplasm of 
lymphoblasts either committed to the B-cell or T-cell lineage. B-ALL is more common than T-ALL 
which accounts for 10-15 % of childhood ALL cases and 25 % of adult cases [21]. Our 
immunophenotypic data show that 64 % of all ALL cases were of the B-cell lineage.  
 
In the WHO 2008 Classification of Tumours of Haematopoietic and Lymphoid Tissues [2], the 
group of B lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities includes the 
four translocations t(9;22)(q34;q11.2); BCR-ABL1 , t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1), 
t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1), and t(v;11q23) MLL rearranged.  
 
The t(9;22)(q34;q11.2); BCR-ABL1 (Ph+) mutation in ALL is more common in adults accounting for 
25% of cases versus 2-4% of childhood ALL and confers a poor prognosis in both age groups [2, 
22]. Its presence in paediatric cases is associated with older age, high white cell count and more 
frequent involvement of the cerebrospinal fluid (CSF) [23]. The use of imatinib in conjunction with 
chemotherapy is associated with an improved event-free survival [24]. 
 
 The t(12;21)(p13;q22);TEL-AML1 (ETV6-RUNX1) and t(1;19)(q23;p13.3);E2A-PBX1 (TCF3-PBX1) 
translocations have prognostic significance in B lymphoblastic leukaemia and are associated with 
a favourable and intermediate prognosis respectively. The t(12;21) mutation is found in 25% of 
cases of B-ALL and results in a fusion protein that interferes with normal function of RUNX1, a 
transcription factor[25]. The t(1;19) mutation is identified in 6% of B-ALL cases. This abnormal 
fusion protein acts as an oncogene which acts as a transcriptional activator and interferes with 
other transcription factors coded by the two genes involvedE2A (E2A/transcription factor 3) and 
PBX1 (pre-B-cell leukaemia homeobox 1) [2, 26]. While originally thought to confer a poor 
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prognosis, more intensive chemotherapy regimens have improved the outcome and it is currently 
considered to have an intermediate prognosis [27]. 
 
The MLL (mixed lineage leukaemia) gene on chromosome 11q23 is associated with many fusion 
partners including ENL (MLLT1) (19p13) and AF9 (MLLT3)(9p22), however, the most common 
gene involved is AF4 (MLLT2) on chromosome 4q21. MLL rearrangements are identified in 80% of 
infant B-ALL cases and 10 % of B-ALL in children [28]. Patients with t(4;11);AF4-MLLtranslocation 
have a poor prognosis, particularly infants less than 6 months of age [2]. 
 
In the T lymphoblastic leukaemia/lymphoma group, an abnormal karyotype is identified in 50-
70% of cases with a wide spectrum of genetic aberrations involving tumour suppressor genes, cell 
signalling pathways, cell cycle regulators and proto-oncogenes. Fifty percent of cases have 
mutations involving the NOTCH1 (Notch homolog 1) gene causing constitutive activation of this 
signalling pathway [29]. Translocations involving MLL occur in 8 % of cases of T-ALL but t(4;11); 
AF4-MLL has not been reported in this subgroup [30]. The t(9;22)(q34;q11.2); BCR-ABL1 mutation 
is identified in <1 % of T-ALL cases and confers a poor prognosis [31].  
1.4 Established Diagnostic Techniques 
The diagnosis of haematological malignancies requires a multidisciplinary approach with several 
techniques utilised, each with their own advantages and disadvantages. With the rapidly 
advancing molecular technologies becoming available, it is essential to evaluate these new 
techniques and assess their potential incorporation in the diagnostic work-up of patients with 
suspected leukaemia. 
 
 
 
 
 
 
10 
 
1.4.1 Non-molecular techniques 
 
Morphology remains an integral part of leukaemia diagnosis. Cytochemical stains are of value in 
both acute leukaemia and myelodysplastic syndromes e.g. in determining granulocytic and 
monocytic components. Immunohistochemistry detects cells with specific antigen expression by 
means of monoclonal or polyclonal antibodies. These methods are labour intensive, time-
consuming and require skill and experience to interpret.  Flow cytometry has the same principle 
as immunohistochemistry with fluorochrome-labelled monoclonal antibodies detecting specific 
antigens on cells. Light scatter patterns are analysed in order to classify populations of cells. This 
method is faster, less labour intensive and analyses large numbers of cells and is particularly 
useful for assessing the presence of antigen co-expression and is a valuable tool for monitoring 
minimal residual disease due to its sensitivity [32, 33].  
1.4.2 Conventional cytogenetics 
 
Conventional cytogenetics remains the gold standard genetic testing method, enabling detection 
of not only common translocations and complex karyotypes, but also numeric aberrations and 
rare translocations which may not be detectable with newer molecular methods [34]. Karyotyping 
is however labour intensive, requires very skilled staff, is time-consuming and dependent on good 
quality sample and cells in metaphase [35] .  Ideally twenty metaphases are analysed depending 
on the quality and if this is not possible, a result may be reported with the number of metaphases 
that could be analysed. The turnaround time (TAT) of conventional cytogenetics in our centre is 
up to 30 days according to the Standard Operating Procedure (SOP). 
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1.4.3 Fluorescence In Situ Hybridisation (FISH) 
FISH analysis uses fluorescent labelled probes to detect specific deoxynucleic acid (DNA) 
sequences of interest. It allows for detection of genetic abnormalities in non-dividing cells, 
provides improved sensitivity and reliability and enables detection of cryptic translocations which 
conventional cytogenetics does not detect e.g. t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) [36-
38].  Owing to the use of specific primers and probes, abnormalities other than the specific 
translocation sought will not be detected by FISH analysis. This technique requires experience and 
skill particularly in interpreting co-localisation or loss of signals [32].  
1.4.4 Polymerase Chain Reaction (PCR) 
 
PCR is the amplification of a specific DNA target flanked by regions of a specific sequence. Primer 
design is therefore a crucial step in ensuring accurate diagnosis. There is also a risk of 
contamination and false negative results, particularly in the case of poor quality DNA. It has a 
greater sensitivity than FISH and cytogenetics and is less labour-intensive. This technique plays an 
integral role in molecular diagnostics e.g. in investigating clonality (T-cell receptor and 
immunoglobulin heavy chain (IgH) rearrangement) and detecting gene rearrangements [32]. 
For RT-PCR, messenger RNA (mRNA) is reverse transcribed to complementary DNA (cDNA) 
followed by amplification. In this way, only exons are targeted for analysis. Multiplex assays have 
been developed to detect several translocations in a single PCR reaction in combination with 
various detection methods including gel-based techniques, capillary electrophoresis, bead array 
or micro-array [39]. 
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1.4.5 Other molecular techniques 
 
For the purposes of this study, the focus will be on the techniques used for routine investigation 
of patients with leukaemia, however many more techniques are already established e.g. 
comparative genomic hybridisation, microarrays and sequencing. Next generation sequencing or 
massively parallel sequencing has been used to sequence entire genomes and has been 
particularly enlightening in the field of AML by identifying more mutations with prognostic and 
treatment implications e.g. Isocitrate dehydrogenase 1 and 2 (IDH 1 and IDH2) and DNA 
methyltransferase 3A (DNMT3A) [40-42].Challenges include its cost and need for sophisticated 
bioinformatics systems.  
There is therefore a need to optimise existing diagnostic techniques to improve detection of 
leukaemia-associated genetic abnormalities in a cost-effective way while providing an efficient 
service with a rapid turnaround time.  
1.5 Multiplex RT-PCR Assays 
 
Multiplex RT-PCR assays offer several advantages. Multiple translocations can be detected in one 
assay which is often more cost-effective and less labour-intensive [43]. Since small amounts of 
RNA are required, these assays can be used on limited diagnostic specimens to screen for several 
fusion transcripts [34, 39] with the potential for a rapid TAT, being as little as five hours in one 
study [43]. Cryptic translocations not detectable by conventional cytogenetics can be identified by 
the multiplex assays.  There are several commercial assays available currently with varied 
performance characteristics for the classification of leukaemias. These include the Signature® LTx 
v2.0 assay (LTx; Asuragen, Austen, TX) and the HemaVision® 7Q (DNA Technoglogy A/S, Aurhus, 
Denmark) assays which will be discussed below. 
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1.5.1 Signature® LTx v2.0 assay 
In the Signature® LTx v2.0 assay, multiplex RT-PCR is combined with multiplex fluorescent bead-
array detection.  Ribose nucleic acid (RNA) is reverse transcribed to cDNA and amplified by 
multiplex PCR.  The PCR product is then hybridised to beads bearing oligonucleotide probes 
specific for each translocation and a reporter molecule is introduced with the fluorescence then 
measured by flow cytometry (Table 1.2). The median fluorescence intensity (MFI) is calculated for 
each and a qualitative result obtained [44]. Chromosome regions tested are the same as those 
targeted by FISH probes at our centre [45] and are represented in Table 1.2. Probes used in FISH 
analysis are the LSI (Locus Specific Identifier) BCR/ABL ES (Extra Signal) dual Colour translocation 
Probe (Vysis, Abbott, Illinois, USA), LSI PML/RARA Dual Colour Translocation Probe (Vysis), LSI 
TEL/AML1 ES Dual Colour Translocation Probe (Vysis), LSI MLL Dual Colour Probe (Vysis), LSI 
TCF3/PBX1 dual colour, dual fusion DNA probe and the LSI CBFB inv(16) dual colour probe.   
 
The Signature® LTx assay was selected for evaluation since the translocations included correlate 
with the FISH analysis probes used at our centre in the diagnostic investigations of patients 
presenting with suspected leukaemia e.g. a new paediatric patient diagnosed with B-cell ALL will 
be tested for t(12;21)(p13;q22) TEL-AML1 (ETV6-RUNX1), t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-
PBX1), t(4;11) AF4-MLLand t(9;22)(q34;q11.2) BCR-ABL. The turnaround time for FISH analysis in 
our centre is 3-10 days for smears and for conventional cytogenetics, 30 days are acceptable 
according to the SOP. Testing for those four translocations in one multiplex assay could 
potentially improve turnaround times as well as total cost considering the price per FISH probe. 
These tests could potentially be performed by staff with a more readily available skill set. 
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Table 1.2: Signature®LTx Leukaemia Translocation Panel v2.0* 
Classification Translocation Fusion transcript and 
Specific variant 
CML t(9;22)(q34;q11) BCR/ABL1 (b2a2) 
BCR/ABL1 (b3a2) 
ALL t(9;22)(q34;q11) BCR/ABL1 (e1a2) 
 t(12;21)(p13;q22) TEL/AML1 (e5/e2) 
 t(1;19)(q23;p13) E2A/PBX1 (e13/e2) 
 t(4;11)(q21;q23) MLL/AF4 (e9/e5) 
MLL/AF4 (e10/e4) 
APL t(15;17)(q24;q21) PML/RARα (L form, 
bcr1) 
PML/RARα (S form, 
bcr3) 
AML Inv(16)(p13;q22) CBFB/MYH11 (A type, 
e5e12) 
CBFB/MYH11 (D type, 
e5e8) 
 t(8;21)(q22;q22) AML1/ETO (e5/e12) 
 
1.5.2 HemaVision® 7Q 
The HemaVision® 7Q is an RT-PCR based multiplex assay for qualitative screening of 7 frequently 
identified translocations involved in CML and Acute Leukaemia as shown in Table 1.3 below. RNA 
is extracted from whole blood or bone marrow followed by cDNA synthesis and qualitative PCR 
analysis. An Internal Amplification Control is included in the assay, as well as a reference gene 
Abelson (ABL1) as a control. If fluorescence exceeds the threshold level before cycle 35 (Ct<35), 
the sample is considered positive for the translocation. The primers in this assay are designed to 
detect multiple breakpoints and splice variants [46].  
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This assay has been evaluated and demonstrated to be cost-effective and showed good 
correlation with routine diagnostic test results, in some cases detecting translocations which 
were not identified by other laboratory assays. These translocations were subsequently 
confirmed using conventional cytogenetics [47].  
The HemaVision ®7Q was initially included in our study protocol, but owing to funding limitations, 
only one multiplex assay was chosen for evaluation at our centre. Both assays are comparable, 
but the Signature® LTx was chosen due to cost per assay. 
Table 1.3: Translocations included in the HemaVision® 7Q assay (adapted from HemaVision® 7Q 
package insert [46]) 
Translocations 
t(1;19)(q23;p13)(TCF3-PBX1) 
t(4;11)(q21;q23)(MLL-AFF1) 
t(8;21)(q22;q22)(RUNX1-RUNX1T1) 
t(9;22)(q34;q11)(BCR-ABL1) – p210, p190 and p230 isoforms 
t(12;21)(p13;q22)(ETV6-RUNX1) 
t(15;17)(q24;q21)(PML-RARA) – L and S isoforms 
inv(16)(p13;q22)(CBFB-MYH11) 
 
1.6 Aim and Objectives 
 
The aim of the study was to compare the multiplex RT-PCR platform Signature® LTx with FISH 
analysis and conventional cytogenetics in the diagnosis of common fusion genes implicated in 
leukaemia. The hypothesis was that this assay is not inferior to gold standard diagnostic methods 
at Charlotte Maxeke Johannesburg Academic Hospital and offers additional advantages of 
improved turnaround time and cost-efficiency.  
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The objectives were 
1. To test samples of patients being investigated for acute leukaemia or CML using the 
commercially available Multiplex RT-PCR assay Signature® LTx. The results will be 
compared to results obtained using FISH and conventional cytogenetics analysis. 
2. To assess the accuracy and usefulness of multiplex RT-PCR methods for the routine 
molecular detection of common leukaemia-associated translocations in our setting and 
thereby determine the feasibility of incorporating the Signature® LTx assay with FISH 
analysis in the diagnostic work-up of patients with leukaemia. 
3. To compare the TAT and cost-effectiveness of the Signature® LTx panel and FISH analysis 
at our centre. 
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2) Materials and Methods 
2.1 Patient samples 
This was a prospective study and sample collection was commenced in June 2013 at CHBAH 
CMJAH, DGMC, from private Clinical Haematologists in Johannesburg as well as Steve Biko 
Academic Hospital (SBAH) as part of our collaboration with the University of Pretoria. A total of 
112 samples were collected with the query of having the diagnosis of leukaemia. Funding was 
available for four assays, each analysing 21 samples therefore a total of 84 samples could be 
tested.  Since some samples had to be discarded throughout the stages of analysis, sample 
collection was extended in order to complete four assays. Reasons for discarding samples will be 
discussed below. 
The bone marrow or peripheral blood samples were taken by the attending 
paediatricians/oncologists after obtaining informed consent during the routine investigation of 
new patients presenting with suspected ALL, AML, APL and CML. 
Exclusion criteria for sample collection were 
 No informed consent obtainable from the patient or parent/legal guardian 
 Difficult aspirate with limited material for routine diagnostic techniques including flow 
cytometry, FISH and cytogenetics analysis 
Patient demographics and results were obtained from the laboratory information system (LIS) 
and included gender, age, sample type (peripheral blood, bone marrow aspirate), cytogenetics 
and FISH analysis results as well as the final diagnosis. Peripheral blood or bone marrow aspirate 
samples were collected in PAXgene RNA tubes (PreAnalytix, Qiagen) and transported to the PCR 
laboratory at CMJAH for storage at -20°C.   
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PAXgene tubes require 2.5 mL of bone marrow aspirate or peripheral blood sample and can be 
stored for three days at room temperature (15-25⁰C), up to five days at 2-8⁰C and for 8 years at -
20⁰C or -70⁰C according to the manufacturer’s specifications. 
2.2 RNA Extraction and quantification 
Initially RNA was extracted from peripheral blood or bone marrow specimens using the 
NucliSENS® easyMAG® (bioMerieux,Lyon, France) as per the standard of practice for our 
laboratory (HAEM1564). Specimens were added to NucliSENS® Lysis Buffer containing guanidine 
thiocyanate and Triton X-100 which inactivates RNases and DNases in the specimen. Magnetic 
silica added to the lysate initiates the isolation process. Nucleic acids present in NucliSENS® Lysis 
Buffer bind the magnetic silica dioxide particles under high salt conditions. The magnetic silica is 
then washed and nucleic acids are eluted form the solid phase making them available for use in 
downstream applications. This technique yielded suboptimal RNA quantities from three test 
samples and an alternative manual extraction technique using the PAXgene Blood RNA Kit 
(PreAnalytix, Qiagen, Limburg, Netherlands) was used for the remainder of the samples.   
The samples were equilibrated and stored for at least 2 hours at room temperature to ensure 
blood cell lysis via the cell lysis buffer already in the tube. All necessary buffers were 
reconstituted and kept at the prescribed temperatures. 
PAXgene tubes (PreAnalytix, Qiagen, Limburg, Netherlands) were centrifuged for 10 minutes at 
3000-5000 x g (times gravity) using a swing-out rotor (Digicen 21R, Ortoalresa, Madrid, Spain). 
The supernatant was removed and 4 mL (millilitres) RNase-free water added to the pellet. The 
tubes were vortexed until the pellet was visibly dissolved and centrifuged again for 10 minutes at 
3000-5000 x g. The supernatant was discarded again and 350 µl (microliters) resuspension buffer 
was added, followed by vortexing. 
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The samples were then transferred to 1.5mL microcentrifuge tubes and 300 µl binding buffer and 
40 µl proteinase K added. The samples were vortexed and incubated for 10 minutes at 55°C using 
a shaker-incubator at 400-1400 rpm (revolutions per minute) (FMH instruments, B&M Scientific 
cc, Helderberg, South Africa). The lysate was then transferred into a PAXgene Shredder spin 
column and centrifuged for 3 minutes at maximum speed (not exceeding 20 000 xg) (Eppendorf, 
Hamburg, Germany).  The supernatant was transferred to a fresh microcentrifuge tube without 
disturbing the pellet. Three hundred and fifty microliters of ethanol (100 % purity grade p.a. pro 
analysi) was added to the tube, followed by vortex and brief centrifuge (1-2 seconds at 500-1000 
x g). A portion of this sample (700 µl) was pipetted into a PAXgene RNA spin column and 
centrifuged for 1 minute at 8000-20 000 xg.  
The spin column was placed in a new 2mL processing tube and the old processing tube containing 
flow-through was discarded. The remaining sample was pipette into the PAXgene RNA spin 
column and centrifuged again for 1 minute at 8000-20 000 xg. A new processing tube was used 
again and the old one discarded. Wash buffer 1 (350 µl) was added to the RNA spin column and 
centrifuged for 1 minute at 8000-20 000 xg. The spin column was placed in a new processing tube 
and the old one discarded. 
DNase I stock solution (10 µl per sample) and DNA digestion buffer (70 µl per sample) were added 
to a 1.5 mL microcentrifuge tube and gently mixed. Eighty microliters of the incubation mix was 
placed onto the PAXgene RNA spin column membrane and left at room temperature for 15 
minutes. 
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This was followed by a series of wash and centrifuge steps as demonstrated in Figure 2.1 below: 
 
Figure 2.1: Wash and centrifuge steps of RNA extraction using the PAXgene Blood RNA Kit 
(PreAnalytix, Qiagen) manual method (adapted with permission from Asuragen package insert 
[44]) 
 
The eluate was incubated for 5 minutes at 65°C (FMH instruments, B&M Scientific cc, Helderberg, 
South Africa) and the samples were transferred to ice and either stored at -20°C or taken to the 
laboratory for RNA quantitation and subsequent RT-PCR steps as shown in Figure 2.2.  
 
Figure 2.2: Signature® LTx workflow adapted from Asuragen package insert [44]. 
(RT – Reverse Transcription; Prep – Preparation; PCR – Polymerase Chain Reaction; Total time estimate ~6 hours) 
350 ul wash buffer 1 into 
PAXgene RNA spin 
column
• Centrifuge for 1 
minute at 8000-20 
000 x g
• Place spin column in 
new processing tube 
and discard old 
processing tube
500 ul wash buffer 2 into 
PAXgene RNA spin 
column
• Centrifuge  for 1 
minute at 8000-20 
000 x g
• Place spin column in 
new processing tube
Add 500 ul wash buffer 
2 to PAXgene RNA spin 
column
• Centrifuge for 3 
minutes at 8000-20 
000 x g
• Discard processing 
tube and place the 
PAXgene RNA spin 
column in a new 
processing tube
• Centrifuge for 1 
minute at 8000-20 
000 x g
• Doscard [rpcessomg 
tibe
Elution step
• Place PAXgene spin 
column in 1.5ml 
microcentrifuge tube 
and pipet 40ul 
elution buffer 
directly onto the 
PAXgene RNA spin 
column membrane.
• Centrifuge for 1 
minute at 8000- 20 
000 x g
• Repeat step as 
described
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Multiplexed translocation analysis testing for the fusion transcripts and an endogenous control 
transcript glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed using the four 
steps: reverse transcription, DNA amplification, hybridisation and detection (Figure 2.3). 
 
RNA quantitation was performed using the Nanodrop spectrophotometer (Thermo Scientific, 
Massachussetts, USA).  According to the PAXgene RNA Kit handbook using the manual protocol, 
A260/A280 ratio of sample absorbance values are recommended to fall between 1.8 and 2.2. The 
recommended RNA concentration is 70 ng/µl [48] but for the purposes of the study, samples 
were only discarded if the concentration was below 20 ng/µl with a note made of the suboptimal 
quantity and compared to the results of the gold standard reference techniques. 
2.3 RT-PCR, DNA amplification and hybridisation 
Once RNA concentration had been determined, we performed reverse transcription of 500ng of 
RNA to cDNA and amplification by multiplex PCR using the GeneAMP PCR System 9700 
Thermocycler (Applied Biosystems, Invitrogen, USA).  A more detailed description of the steps 
involved is given in Figure 2.3. 
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Figure 2.3: Detailed Workflow for steps 1-3: Reverse transcription, DNA Amplification and 
Hybridisation (Adapted from Asuragen package insert [44]). 
(MMLV RT – Moloney murine leukaemia virus reverse transcriptase; AMP – amplification) 
A total of 5μl PCR product was hybridised to a mixture of 12 probes conjugated to 12 unique 
carboxylated xMAP beads (Luminex Corp., Austin, TX, USA). This was done using the Bio-Rad Bio-
Plex™ 200 instrument and Bio-Plex Manager™ software (Luminex, Texas, USA) for analysis. A 
minimum of 50 beads for each fusion transcript and the endogenous control GAPDH was analysed 
to determine the MFI signal for each probe. The positive, negative and no RNA controls included 
in the assay was included in every run. The Signature® LTx negative control contains only the 
GAPDH transcript and the positive control is an RNA sample containing the GAPDH transcript and 
all fusion transcripts detected by the assay [44]. 
Reverse Transcription
•Prepare mixture of RNA and RT 
primers: 4 μl of Signature® LTx 
v2.) RT-Primer mix into 
individual RT reactions. Add up 
to 6 μl of sample total RNA (400-
1000ng). Add Signature® LTx 
v2.0 Diluent to formulate final 
individual reaction volumes of 
10μl.
•For controls use 3 μl of Control 
and 3μl of Signature® LTx v2.0 
Diluent
•Thermal cycler at 70°C for 5 
minutes 
•Prepare master mix: 4 μl of 
Signature® LTx v2.0 RT Buffer I,  
4 μl of Signature® LTx v2.0 RT 
Buffer II, 1 μl Signature® LTx v2.0  
RNase Inhibitor and 1 μl of 
Signature® LTx v2.0 MMLV RT
•Add 10 μl of the RT Master Mix 
into each reaction containing 
annealed RNA/RT Primer mix
•Transfer reactions to thermal 
cycler and cover with RT 
compression pad
•Run program: 42°C 45 minutes, 
93°C 10 minutes, hold at 4°C
•cDNA product can be stored at -
15 to -30°C
DNA Amplification
•Thaw samples
•Prepare DNA Amplification 
Master Mix for total number of 
samples to be tested
•Add components: 5 μl 
Signature® LTx v2.0  DNA Amp 
Buffer, 5 μl Signature® LTx v2.0  
DNA primer mix, 9 μl Signature® 
LTx v2.0  Diluent, 0.5 μl 
AmpliTaq Gold, 0.5μl Signature® 
LTx v2.0  Diluent
•Add 20 μl DNA Amp Master Mix 
to each DNA Amp tube or 
reaction plate well
•Add 5 μl of cDNA product to 
each tube or well to achieve final 
reaction volume of 25 μl
•Transfer to thermal cycler: 37°C 
15 minutes, 95°C 10 minutes,
•45 cycles of 94°C for 30 seconds,  
55°C for 30 seconds, 72°C for 30 
seconds
•Amplified product can be stored 
at 2-8°C in the dark for up to 48 
hours
Hybridisation
•Vortex (3x5 sec) and sonicate 
(3x5 sec) Signature® LTx v2.0 
Bead Mix before use
•Add 45 μl of Signature® LTx v2.0  
Bead Mix to each well of new 
hybridisation plate
•Remove plate seal from DNA 
amplification reactions and 
transfer 5 μl of well-mixed 
amplified product to the 
corresponding wells
•Transfer to thermal cycler and 
cover wtih RT compression pad
•Run program: 95°C for 5 
minutes, 52°C for 25 minutes, 
52°C hold for 10 minutes with 
plate covered
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After completion, output files were converted to Excel spreadsheet and results analysed based on 
MFI cut off as per the manufacturer’s instructions [44] 
2.4 Analysis of Signature® LTx results 
Samples were designated as negative or positive for a translocation relevant to the Signature® LTx 
multiplex RT-PCR assay as determined by cytogenetics and FISH analysis e.g. a sample showing 
MLL rearrangement with t(10;11) on cytogenetic analysis was still classified as negative as the 
multiplex assay can only detect the t(4;11) AF4-MLL fusion partner. The results of the FISH 
analysis and cytogenetics results were then compared to the transcripts identified by our 
multiplex assay with an MFI of 350 as the cut off signal for the presence of a specific fusion 
transcript as per the manufacturer’s specifications and confirmed by other multicentre validations 
of the assay [48]. Mean MFIs for all positive and negative transcripts were also calculated. 
 
According to the manufacturer’s protocol, an invalid control result (Table 2.1) would include a 
positive control with any fusion transcript <350 MFI or GAPDH <1000 MFI; a negative control with 
any fusion transcript >350MFI or GAPDH <1000 MFI or a bead count for any bead <50 [44].  These 
results would require re-run of the plate from the reverse transcription step or the hybridisation 
step in the case of a low bead count. For research purposes however, we could not repeat testing 
owing to limited assays and ‘invalid’ control results were still accepted for analysis with 
description of the problem encountered. Valid control results would include a positive control 
with fusion transcripts >350MFI and GAPDH >1000 MFI and a negative control with fusion 
transcripts <350MFI and GAPDH of >1000 MFI. 
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Table 2.1: Control results - Description of invalid and valid control results as per manufacturer’s 
recommendation adapted from Asuragen package insert [44]). 
Run Sample Result Re-test 
Invalid (One or more 
controls are invalid) 
Positive control Fusion transcript <350 
MFI or GAPDH < 1000 
MFI 
Re-run from reverse 
transcription step* 
Negative control Fusion transcript >350 or 
GAPDH < 1000 MFI 
Re-run from reverse 
transcription step 
Any LTx control Low bead count for any 
bead 
Re-run from 
hybridisation step 
Valid control result Positive control All fusion transcripts 
>350 MFI and GAPDH > 
1000 MFI 
N/A 
Negative control All fusion transcripts 
<350 MFI and GAPDH > 
1000 MFI 
N/A 
(* This was not done for the purposes of this evaluation and all results were included for analysis, for reasons provided 
above.) 
 
For diagnosis runs would be deemed invalid if there is a low bead count for any bead or all fusion 
transcripts of <350MFI and GAPDH <1000 MFI (Table 2.2). This would require a re-run from the 
hybridisation step in the case of a low bead count; or a re-run from the reverse transcription step 
or re-extraction of RNA from the same sample in the case of GAPDH <1000 MFI.  For our 
purposes, a GAPDH signal of <1000 MFI was still accepted and the result was compared with 
those of cytogenetics and FISH analysis for any discrepancies.  A tested sample would be called 
positive for a fusion transcript if a MFI of greater than 350 MFI is generated and negative if all 
fusion transcripts are <350 MFI and GAPDH >1000 MFI [44].  
 
Genetic mutations other than those included in the Signature® LTx Multiplex RT-PCR assay were 
also documented in order to recommend alterations or additions to the assay. 
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Table 2.2: Sample results - Description of valid and invalid patient sample results as per 
manufacturer’s recommendation as adapted from Asuragen package insert [44]. 
Run Sample Result Interpretation Re-test 
Valid 
(Bead 
count for 
every 
control 
bead >50 
and all 
control 
results 
valid) 
Tested 
sample 
All fusion transcripts <350 
MFI and GAPDH < 1000 
Invalid 
samples result 
Re-run from reverse 
transcription or re-extract RNA 
from same/new specimen 
Low bead count for any 
bead 
Invalid sample 
result 
Re-run from hybridisation step 
Any fusion transcript 
>350 MFI 
Fusion 
transcript 
detected 
N/A 
All fusion transcripts <350 
MFI and GAPDH > 1000 
MFI 
Fusion 
transcripts not 
detected 
N/A 
 
2.5 Fluorescence in situ hybridisation 
FISH was performed by the staff of the Somatic Cell Genetics Unit in the NHLS, CMJAH as per 
standard operating procedure (SOP HAE0234).  
2.5.1 Sample preparation and pre-treatment 
Peripheral blood or bone marrow collected in an ethylenediaminetetra-acetic acid (EDTA) or 
heparin tube is the ideal material, alternatively unstained smears can be used. The sample should 
be processed as soon as possible, preferably within 2 days. The sample is centrifuged for 10 
minutes at 1500 rpm. With a glass Pasteur pipette, a drop of buffy coat about 2 mm in diameter is 
placed 10 mm from the frosted area and spread with a spreader at 30⁰ angle. The smear dries for 
10 minutes at room temperature.  
The slides are placed in Coplin jars filled with methanol for 30 minutes at -20⁰C followed by 2 
hours in a fixative filled Coplin jar. The slides are dehydrated in a series of ethanol solutions 
graduating from 70 %, 90 % and 100 % for 5 minutes each at room temperature. Slides are placed 
in protease solution for 10 minutes at 37⁰C, washed and fixed in 1 % formaldehyde for 5 minutes. 
After another wash, the slides are dehydrated again in 70, 90 and 100 % ethanol for 1 minute 
each.  
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2.5.2 Hybridisation 
Slides are dried and warmed at 60⁰C for 5 minutes. They are then placed in a denaturing solution 
for 5 minutes in a water bath set at 76⁰C. The slides are then transferred into ice cold ethanol (70 
%, 90 % and 100 %) for 5 minutes each on a shaker and dried in an upright position. Probes are 
prepared just before the denaturing step and denatured at 76⁰C for 5 minutes while the slides are 
in 90% ethanol on the shaker. Ten microlitres of probe mixture is added onto the slide with a 
pipette and a coverslip is applied followed by sealing with rubber cement. Slides are then 
incubated at 37⁰C overnight.  
2.5.3 Washing 
After incubation, the rubber cement is removed and the slides are treated with several washing 
steps as well as addition of 50 µl DAPI (4’, 6-Diamidino-2-Phenylindole double stranded DNA 
staining). The slides are kept in the dark and analysed with a fluorescent microscope with various 
filters and objectives for analysis.  
2.5.4 Analysis and reporting results 
One to two hundred cells are analysed by a trained technologist/scientist and checked by a senior 
member of staff. Findings are recorded on an analysis sheet and reported as a percentage. 
Nomenclature is used according to the (SICN) 2013 International System for Human Cytogenetic 
Nomenclature.  
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2.6 Conventional Cytogenetics 
Testing and analysis of all samples were performed by the Somatic Cell Genetics Unit in the NHLS, 
CMJAH as per standard operating procedure (SOP HAE0221 and HAE0224). 
2.6.1 Initiation of culture 
One to five millilitres of peripheral blood collected in a sodium heparin vacutainer or 1.0-2.0mL of 
fresh bone marrow obtained from the initial aspirate are used for testing.  Cultures were 
performed within 24 hours of bone marrow collection. The specimen is centrifuged in transport 
media tube at 1500 rpm for 10 minutes at room temperature followed by removal of most of the 
supernatant. The remaining pellet is re-suspended with the remaining supernatant. Fifteen to 
thirty drops (0.25-0.50 mL) of suspension is added to sterile 50 mL culture flasks containing 3-5 
mL of supplemented medium. The flasks are incubated at 37⁰C overnight.  
2.6.2 Harvesting 
For harvesting, the culture is centrifuged at 1500 rpm for 8-10 minutes and the supernatant 
removed. Colcemid (0.1 mL) and warm potassium chloride (KCl) (6.0 mL) are added followed by 
mixing and incubation for 25 minutes. Three drops of cold 3:1 methanol-ascetic acid (fixative) is 
added followed by mixing and centrifugation. After the supernatant has been removed, the pellet 
is re-suspended and 5mL of cold 3:1 fixative is added followed by thorough mixing. Second and 
third fix and centrifuge steps follow and the tubes can be stored at -20⁰C until slide making is 
required. 
2.6.3 Slide preparation 
Slide preparations involved dropping harvested cell suspensions on a slide flooding with fixative 
and air-drying. The slide is flooded with fresh 3:1 methanol-acetic acid fixative followed by 3 
drops of cell suspension. The slide is steamed and aged in the oven at 90⁰C for 45 minutes to 2 
hours. Slides are dipped in room temperature trypsin for 5-60 seconds and rinsed briefly in Coplin 
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jars containing 0.9% NaCl. Trypsin interacts with the protein-DNA complex and creates a staining 
differential between condensed and less condensed sections. Finally, the slide is stained for 1-3 
minutes with Wright’s stain-buffer solution (0.1 mL stain and 4.0 mL buffer) followed by rinsing 
and blot drying with tissue paper.  Wright’s stain creating a pattern of light and dark bands. Each 
chromosome has a characteristic pattern for identification. 
Adequately prepared slides should yield well spread mitotic figures for G0banding and 
chromosome analysis.  
2.6.4 Analysis and reporting of results 
Slides are examined for metaphases and if the metaphase spread is suitable, a more detailed 
examination is performed. For photography and karyotyping, a semi-automated chromoscan 
system (Cytovision, Leica Biosystems, IL, USA) and the karyotype is reported with tabulation of 
cells analysed, chromosome counts and karyotyping according to the International System for 
Human Cytogenetic Nomenclature (ISCN 2005). Twenty metaphases are analysed ideally, if fewer 
are obtained this is stated in the report.  
2.7 Statistical analysis 
Percent agreements were calculated using the GraphPad Prism version 4.00 for Windows 
(GraphPad Softward, San Diego, CA), comparing the qualitative results with the gold standard 
cytogenetics and FISH analysis. Quantitative analysis of the signal distributions for each type of 
signal; positive, negative and endogenous control was done using box plots. Analysis of variance 
(ANOVA) testing was used to calculate significant difference in means of the positive, negative 
and internal controls and a post hoc analysis was done to determine between which means there 
is a difference in order to ensure correct cut off values in terms of mean fluorescence intensity 
and determine the robustness of the assay with regards to the GAPDH as internal control. The 
mean MFI signals for all positive and all negative transcripts were also calculated. 
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3) Results 
3.1. Patient samples 
 
A total of 112 samples were collected with the suspected diagnosis of leukaemia. Of these, 6 
were discarded once a diagnosis other than ALL, AML, CML and APL was confirmed as shown in 
Figure 3.1. The remaining 106 peripheral blood and bone marrow aspirate samples were stored 
for analysis in batches. The details of all collected samples are shown in the Table 3.1 below. 
Thirty five (34.31%) peripheral blood and 67 (65.69 %) bone marrow aspirate samples were 
collected.  
 
Figure 3.1: Flow diagram of all samples collected and analysed. 
A total of 112 samples were collected, six discarded with diagnoses other than ALL, AML, APL or CML.  A further 24 
samples were discarded during RNA extraction and 12 were considered of inadequate RNA quantity. A final total of 70 
samples could yield results for comparison to FISH and cytogenetics results. 
 
Fifty three (51.96 %) male patients and 49 (48.04 %) female patients agreed to participate in the 
study (Table 3.1). Of the samples, 55 (53.92 %) were from paediatric oncology units (0-18 years) 
and 47 (46.08 %) from the adult oncology patients (18 years and older). The final diagnoses after 
initial investigations were 9 CML cases (8.82 %), 30 B-cell ALL cases (29.41 %), 12 T-cell ALL cases 
(11.76 %), 2 cases of ambiguous lineage leukaemia (1.96 %), 11 cases of APL (10.78 %) and 38 
cases of AML (37.25 %) as shown in Table 3.2.  
112 
samples 
collected
Discarded if 
no 
diagnosis of 
ALL, AML, 
APL or CML
n = 6
Samples 
discarded 
during RNA 
extraction 
n = 24
Inadequate 
RNA 
quantity 
(<20 ng/ul)
n = 12
Samples 
analysed 
with 
Signature® 
LTx assay
n = 70
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These numbers correlated with those collected from the flow cytometry register in the case of 
APL, AML and T-ALL, however our sample group had more cases of B-ALL and fewer cases of CML.  
Table 3.1: Details of all collected samples (n = 106) 
Gender 
Male 
Female 
Number (%) 
57 (53.77) 
49 (46.23) 
Age, n (%) 
Paediatric (0-18 yrs) 
Adult (>18 yrs) 
 
55 (51.89) 
51 (48.11) 
Sample type 
Peripheral blood (PB) 
Bone marrow aspirate (BM) 
 
35 (33.02) 
71 (66.98 
 
 
All patients had either cytogenetics or FISH analysis results on the laboratory information system 
(Figure 3.2). Cytogenetics results were available for 64 of the 70 patients. In two cases, no 
cytogenetics analysis was requested and in four cases, there were no adequate metaphases for 
analysis. All six cases had FISH analysis results, with a translocation or deletion detected in four 
patient samples. Of all the cytogenetics results, less than 20 metaphases were analysed in 35 
cases. FISH analysis was not requested or had been performed at the referral institute before 
transfer of the patient in four cases and cytogenetics results were available for all these patients. 
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Figure 3.2: Cytogenetics and FISH analysis availability for all samples analysed using the 
multiplex assay 
Of all the samples, FISH analysis was available for 66 cases and in the four where FISH was not requested, a 
cytogenetics report was issued. In the 70 samples analysed, cytogenetics results were available for 64, of which 38 had 
fewer than the ideal twenty metaphases. 
For the translocations included in the Signature® LTx multiplex RT-PCR assay,  a total of 51 cases 
were positive by FISH or cytogenetic analysis including 10 cases of t(8;21)(q22:q22); RUNX1-
RUNX1T1, 3 cases of inv (16)(p13.1q22); CBFB-MYH11 and 11 cases of t(15;17)(q24;q21); PML-
RARa. In the ALL category, 9 cases of t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1), 3 cases of 
t(9;22)(q34;q11.2); BCR-ABL1and five cases of t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) were 
identified. In keeping with the nine diagnoses of CML, nine t(9;22)(q34;q11.2); BCR-ABL1 
mutations were positive using FISH or cytogenetic analysis (Table 3.2).  
The samples were both extracted and run in batches from June to end of July 2014. Since samples 
had to be discarded during and after the extraction process, an additional assay remained and 
sample collection was extended until December 2014 with the final analysis completed in the 
same month. 
 
All samples
n = 70
FISH analysis
Not requested 
n = 4 (5.71 %)
Cytogenetics 
results available
n = 4 (100.00 %)
Requested 
n = 66 (94.29 %)
Cytogenetics
No metaphases
n = 6 (8.57 %)
FISH results 
available
n = 6 (100.00 %)
Result available
n = 64 (91.43 %)
Metaphases <20
n = 38 (59.38 %)
Metaphases >20
n = 26 (40.63 %)
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Table 3.2 Details of patient diagnosis, conventional cytogenetics and FISH analysis results 
(relevant to Signature® LT Multiplex RT-PCR assay) of all collected samples (n = 102) 
Diagnosis 
Total number, n (%) 
Chromosomal 
target 
Fusion transcript Number 
(%) 
Chronic myeloid leukaemia, 
9 (8.82) 
t(9;22)(q34;q11) BCR-ABL1 9 (8.82) 
Acute promyelocytic 
leukaemia, 
11 (10.78) 
t(15;17)(q24;q21) PML-RARa 11 
(10.78) 
Acute myeloid leukaemia, 
38 (37.25) 
t(8;21)(q22;q22) RUNX1-RUNX1T1 10 
(9.80) 
 inv(16)(p13;q22) CBFB-MYH11 3 (2.94) 
 Other mutations  25 
(24.51) 
Acute lymphoblastic 
leukaemia,* 
42 (41.18) 
t(9;22)(q34;q11) BCR-ABL1 3 (2.94) 
 t(12;21)(p13;q22) ETV6-RUNX1 (TEL-AML1) 5 (4.90) 
 t(1;19)(q23;p13) TCF3-PBX1 (E2A-PBX1) 9 (8.82) 
 Other mutations  25 
(24.51) 
Ambiguous lineage acute 
leukaemia, 2 (1.96) 
  2 (1.96) 
 
[* B-cell Acute Lymphoblastic Leukaemia n=30 (29.41), T-cell Acute Lymphoblastic Leukaemia n = 12 (11.76)] 
3.2 RNA extraction and quantification 
Total RNA was initially isolated from peripheral blood or bone marrow specimen using the 
NucliSENS® easyMAG® (bioMerieux,Lyon, France). This however yielded suboptimal RNA quality 
and quantity despite troubleshooting and a manual extraction kit PAXgene Blood RNA Kit 
(PreAnalytix, Qiagen) was ordered. The manual extraction yielded better RNA concentration 
(ng/µl) and quality (A260/A280 ratio of sample absorbance). During RNA extraction however, 24 of 
the 102 samples (23.53%) were discarded as they became viscous after the incubation step at 
55°C (Figure 3.1). Furthermore, an additional 12 out of 102 samples (11.76 %) could not be used 
in the RT-PCR step as the RNA concentration was below 20 ng/µl (Figure 5). Although the 
manufacturer’s instructions recommend a target of 70 ng/µl, samples between 20 and 70 ng/µl 
were included for analysis. All the samples met the criterion of absorbance value A260/A280 ratio 
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between 1.8 and 2.2. This resulted in 70 samples meeting the required criteria for analysis. Of 
note was that samples which had been stored for less than six months yielded better RNA 
concentration and were less likely to be discarded during the extraction process (Table 3.3). 
Table 3.3: Number of samples discarded after 1 year of storage (June-July 2014) and after 6 
months of storage (December 2014) 
 Analysis (June – July 2014) Analysis (December 2014) 
Number of samples discarded 
(% of total samples collected) 
33 (32.35) 3 (2.94) 
Median RNA concentration 
(ng/µl) 
107.3 205.2 
 
3.3 RT-PCR, DNA amplification and hybridisation 
 
Samples were run and analysed and the results compared with those obtained by FISH and 
cytogenetics analysis. Forty nine samples (70.00 %) were bone marrow aspirate and 21 (30.00 %) 
were peripheral blood (Table 3.3). The samples analysed were collected form 40 males and 30 
females. Thirty nine paediatric samples could be included in the run and 31 adult samples with 4 
cases of CML, 23 cases of B-cell ALL, 5 cases of T-cell ALL, 1 case of ambiguous lineage acute 
leukaemia, 6 APL cases and 27 AML cases (Table 3.4).  
Despite having to discard samples, a good representation of all included translocations was still 
achieved including 8 samples with t(8;21)(q22:q22); RUNX1-RUNX1T1, 2 cases of inv 
(16)(p13.1q22); CBFB-MYH11, 6 cases of t(15;17)(q24;q21;) PML-RARa, 8 cases of 
t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1), 1 case of t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1), 
2 cases of t(9;22)(q34;q11.2); BCR-ABL1in the setting of ALL and 4 cases of t(9;22)(q34;q11.2); 
BCR-ABL1with a diagnosis of CML (Table 3.5).  
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Table 3.4: Details of all analysed samples (n = 70) 
Gender, n (%) 
Male 
Female 
 
40 (57.14) 
30 (42.86) 
Age, n (%) 
Paediatric (0-18 yrs) 
Adult (>18 yrs) 
 
39 (55.71) 
31 (44.29) 
Sample type 
Peripheral blood (PB) 
Bone marrow aspirate (BM) 
 
21 (30.00) 
49 (70.00) 
 
 
Table 3.5 Details of patient diagnosis, conventional cytogenetics and FISH analysis results 
(relevant to Signature® LT Multiplex RT-PCR assay) of all analysed samples (n = 70) 
Diagnosis 
Total number, n (%) 
Chromosomal 
target 
Fusion transcript Number (%) 
Chronic Myeloid Leukaemia, 
4 (5.71) 
t(9;22)(q34;q11) BCR-ABL1 4 (5.71) 
Acute Promyelocytic 
Leukaemia, 
6 (8.57) 
t(15;17)(q24;q21) PML-RARa 6 (8.57) 
Acute Myeloid Leukaemia, 
31 (44.29) 
t(8;21)(q22;q22) RUNX1-RUNX1T1 8 (11.43) 
  inv(16)(p13;q22) CBFB-MYH11 2 (2.86) 
  Other mutations  21 (30.00) 
Acute Lymphoblastic 
Leukaemia,* 28 (40.00)  
t(9;22)(q34;q11) BCR-ABL1 2 (2.86) 
  t(12;21)(p13;q22) ETV6-RUNx1 (TEL-AML1) 1 (1.43) 
  t(1;19)(q23;p13) TCF3-PBX1 (E2A-PBX1) 8 (11.43) 
  Other mutations  17 (24.29) 
Ambiguous lineage acute 
leukaemia, 1 (1.43) 
    1 (1.43) 
[* B-cell Acute Lymphoblastic Leukaemia n=23 (32.86), T-cell Acute Lymphoblastic Leukaemia n = 5 (7.14)] 
3.4 Analysis of Signature® LTx results 
After testing was completed, Excel spreadsheets were generated and data captured with regards 
to controls and transcripts. The GAPDH signals of less than 1000 MFI were still accepted for 
analysis and a cut-off of 350 MFI was used to determine positive transcripts. These results were 
then compared to cytogenetics and FISH analysis results. Of the 70 samples suitable for analysis, 
FISH/cytogenetics detected 31 translocations corresponding to those included in the Signature® 
LTx Multiplex RT-PCR assay (Figure 3.3).  Of these, the result was confirmed using the Signature® 
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LTx Multiplex RT-PCR assay in 25 cases (81.00 %) with discordant results in 6 samples (19.00 %). In 
the 39 cases of no detection of one of the 12 multiplex assay translocations by FISH/cytogenetics 
analysis, 35 (90.00 %) were also negative using the Signature® LTx Multiplex RT-PCR assay where 
it detected 4 translocations not demonstrated with gold standard genetic testing techniques.  
 
Figure 3.3: Flow chart of samples evaluated. A mutation was considered to be present if it was 
identified on FISH/cytogenetics and it was included in the multiplex PCR kit as shown in Table 
1.2. 
 
Tables 3.6-3.7 show a summary of all concordant (n = 60) results and Table 3.8 all discordant (n = 
10) results including information on the RNA quantity, quality and GAPDH signal. In three of the 
four runs all the controls passed, however in the third analysis the positive control GAPDH was 
less than 1000 MFI (please refer to notes in Table 2.1). In this same run, 14 of the 21 samples had 
GAPDH levels <1000, however of these, only two results were discrepant (BP12 and GA18 in Table 
3.8) with those reported on FISH or cytogenetics analysis. In some runs, samples (n = 10) were 
included despite not meeting the RNA concentration limit of 70 ng/µl. Of these samples, results 
correlated with gold standard methods result in seven cases.  
 
Signature LTx 
Multiplex Assay
Cytogenetics / FISH  
results
Total number of 
samples analysed
n =70
Mutation present
n=31
44.29 %
Correctly 
identified
n = 25
80.65 %
Mutation not 
identified
n= 6 
19.35 %
No mutation
n= 39 
55.71 %
No mutation 
identified
n=  35
89.74 %
Mutation 
identified 
n= 4 
10.26 %
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A total of 10 cases as described in the flow diagram above did not correlate with each other as 
shown in Table 3.8 - mutation not identified by the Signature® LTx Multiplex RT-PCR assay (n=6) 
and mutation identified by the Signature® LTx Multiplex RT-PCR assay which had not been 
detected by FISH or cytogenetics (n=4).Missed mutations included inv(16) (p13.1q22) CBFB-
MYH11, t(15;17)(q22;q12); PML-RARA and t(9;22)(q34;q11.2) BCR-ABL1 and three 
t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1) mutations.  
 
A borderline of MFI (365) was detected in one case for mutation t(8;21)(q22:q22) RUNX1-
RUNX1T1 while the other routine results (FISH analysis and cytogenetics)for this sample showed 
no translocations (See Table 3.8). Another t(8;21)(q22:q22) RUNX1-RUNX1T1 (MFI 417.5) was 
identified in a paediatric patient with B-ALL showing aberrant myeloid marker expression. The 
third discrepant t(8;21)(q22:q22) RUNX1-RUNX1T1 was also detected in an adult patient, a 
mutation which was not detected using cytogenetics and no FISH was requested for the patient. 
In this case the MFI was strongly positive at 5961 MFI. Finally, BP2 had FISH results showing 
rearrangement of the MLL gene and cytogenetic studies identified an unknown translocation 
partner t(11;?). Subsequently, a t(4;11) MLL/AF4 was identified using our assay, but it could not 
be confirmed. 
 
Table 3.9 shows the further inspection of discrepant results with regards to specific categories of 
RNA quantity (<70mg/µl), GAPDH signal (<1000 MFI), borderline MFI signals and suboptimal 
quality of the gold standard testing technique. 
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Table 3.6: Summary of all concordant results (positive for translocations relative to the 
Signature® LTx Multiplex RT-PCR assay) 
Patient 
code 
RNA ng/ul A260:A280 GAPDH 
MFI 
Fusion 
transcript 
MFI 
Signature 
results 
FISH/cytogenetics 
results 
 t(8;21)(q22;q22) AML-ETO  
BA8 146.5 2.07 5353 8190 t(8;21) t(8;21) 
DP9 211.2 2.05 6239 8937 t(8;21) t(8;21) 
GA7 66.6* 1.98 6511 9213 t(8;21) t(8;21) 
GA15 979.6 2.10 5585 8680 t(8;21) t(8;21) 
BA20 266.5 2.07 46* 3638 t(8;21) t(8;21) 
BA10 140.1 2.14 2565 7273 t(8;21) t(8;21) 
GA22 111.1 2.14 3540 8256 t(8;21) t(8;21) 
BA12 273.4 2.08 223* 3456 t(8;21) t(8;21) 
 inv(16)(p13;q22) CBFB-MYH11  
GP4 85.0 1.97 6700 8366; 2902 inv(16) Inv(16) 
 t(15;17)(q24;q21) PML-RARα  
BP15 58.9* 2.07 5413 8163 t(15;17) L t(15;17) 
GA1 11.4* 2.44 3563 4371 t(15;17) L t(15;17) 
GA5 464.4 2.02 6438 7831; 1874 t(15;17) L&S t(15;17) 
BP8 951.0 2.10 2609 5027 t(15;17) L t(15;17) 
BA9 363.4 2.07 2076 5157 t(15;17) L t(15;17) 
 t(9;22)(q34;q11) BCR-ABL1 (b2a2) 
GA10 78.4 2.01 3032 6864 t(9;22)  t(9;22) 
BP1 131.7 2.11 2375 5972 t(9;22)  t(9;22) 
GA9 417.1 2.01 1233 1353 t(9;22)  t(9;22) 
 t(9;22)(q34;q11) BCR-ABL1 (b3a2) 
BA13 229.4 2.12 1265 2131 t(9;22) t(9;22) 
 t(9;22)(q34;q11) BCR-ABL1 (e1a2)  
DP7 188.2 2.08 959* 5004 t(9;22) t(9;22) 
 t(1;19)(q23;p13) E2A-PBX1 
BP13 93.1 2.07 49* 2658 t(1;19) t(1;19) 
BP20 569.8 1.94 608* 1100 t(1;19) t(1;19) 
GP5 109.9 2.06 91* 2163 t(1;19) t(1;19) 
DP18 114.9 2.10 3969 7064 t(1;19) t(1;19) 
DP17 52.5* 2.09 2385 6894 t(1;19) t(1;19) 
 t(12;21)(p13;q22) TEL-AML1  
BP4 214.4 2.09 5522 2171 t(12;21) t(12;21) 
   
(* Indicates suboptimal RNA quantity or GAPDH MFI signal) 
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Table 3.7: Summary of all concordant results (negative) for translocations relative to the 
Signature® LTx Multiplex RT-PCR assay 
Patient 
code 
RNA 
ng/µl 
A260:A280 GAPDH 
MFI 
Signature 
results 
FISH/cytogenetics 
results 
Negative 
SP1 988.7 2.10 7306 Neg Neg  
GP8 230.1 2.10 5963 Neg Neg 
DP1 38.9* 1.97 2953 Neg Neg 
GA13 17.9* 2.18 4237 Neg Neg 
BA6 332.0 2.07 7081 Neg Neg 
GP1 73.6 2.09 4376 Neg Neg 
DP3 77.8 2.06 1867 Neg Neg 
BP7 182.9 2.05 7321 Neg Neg 
BP5 89.2 2.02 866 Neg Neg 
GA12 355.5 2.03 7497 Neg Neg 
GP3 65.8* 2.01 6493 Neg Neg 
BP14 83.1 1.96 202* Neg Neg 
GP6 274.0 2.08 2362 Neg Neg 
BP3 133.9 1.99 1626 Neg Neg 
BA5 61.3* 2.01 196* Neg Neg 
BP6 58.6* 2.05 29* Neg Neg 
DP11 824.0 2.12 629* Neg Neg 
DP13 255.3 2.05 2375 Neg Neg 
BP22 376.3 2.02 6200 Neg Neg 
BA21 192.8 2.08 4478 Neg Neg 
GP11 118.2 2.10 5277 Neg Neg 
GA23 216.8 2.01 6131 Neg Neg 
BP26 100.8 2.07 5243 Neg Neg 
BP25 139.7 2.09 6170 Neg Neg 
GA20 160.6 2.10 6774 Neg Neg 
DP14 108.3 1.97 5620 Neg Neg 
GA21 40.5* 2.18 6483 Neg Neg 
BP23 176.7 1.94 5773 Neg Neg 
SB1 145.7 1.96 6449 Neg Neg 
SB2 130.5 1.98 3471 Neg Neg 
SB3 191.4 1.96 7127 Neg Neg  
SB4 137.0 2.05 5832 Neg Neg**  
SB5 155.0 1.90 5138 Neg Neg  
GA4 49.0* 2.12 4272 Neg Neg 
DP4 122.6 2.07 6362 Neg Neg 
(* Indicates suboptimal RNA quantity or GAPDH MFI signal; ** Unusual signal pattern with probe results despite 
rearrangement of chromosome 16) 
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Table 3.8: Summary of all discordant results (n = 10) 
Diagnosis Patient code RNA 
ng/µl 
A260:
A280 
GAPDH 
MFI 
Fusion 
transcript 
MFI 
Signature 
results 
FISH/cytogenetics 
results 
AML inv(16)(p13;q22) CBFB-MYH11  
 DP2 27.6* 2.49 2324 100; 73 Neg inv(16) 
   
APL t(15;17)(q24;q21) PML-RARα  
 DP15 164.2 2.09 5830 38; 64 Neg t(15;17) 
   
ALL t(9;22)(q34;q11) BCR-ABL1 (e1a2)  
 DP5 71.5 2.03 93* 92 Neg t(9;22) 
   
ALL t(1;19)(q23;p13) E2A-PBX1  
 BA1 50.5* 2.11 4524 113 Neg t(1;19) 
 BP12 627.7 2.12 17* 113 Neg t(1;19) 
 GA18 299.9 2.09 194* 41 Neg t(1;19) 
   
Mixed 
cases 
Negative 
ALL BP2  106.7 2.09 192* 4316 t(4;11) MLL rearrangement 
AML GA6 82.9 2.00 640* 5961 t(8;21) Neg 
AML GA8 22.1* 2.12 4360 365 t(8;21)  Neg 
ALL GP9 262.5 2.09 3608 418 t(8;21)  Neg 
* Indicates suboptimal RNA quantity or GAPDH MFI signal 
 
Table 3.9: Deviations of optimal criteria noted in discrepant samples 
Patient code RNA 
concentration 
(<70ng/µl) 
GAPDH 
signal (<1000 
MFI) 
Borderline 
MFI* 
Suboptimal quality 
gold standard (<20 
metaphases) 
DP2 x (27.6)    
DP15    X (13) 
DP5  x (198.0)   
BA1 x (50.5)    
BP12  x (865.5)   
GA18  x (194.0)  x (10) 
BP2  x (192.0)   x (6) 
GA6  x (640.0)  x (2) 
GA8 x (22.1)  X (356) x (10) 
GP9   X (418)  
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According to the manufacturer’s specifications, the required RNA concentration is > 70ng/µl and a 
GAPDH signal of <1000 MFI would require re-run from the reverse transcription step. For the 
purposes of our study we did not repeat steps or repeat extraction. If we strictly adhered to these 
recommendations, the following numbers of concordant and discordant results would be 
obtained (Figure 3.4). 
 
Figure 3.4: Summary of concordant and discordant results with strict adherence to RNA 
quantity and GAPDH signal requirements. 
The box plot in Figure 3.5 shows quantitative analysis of signal output with the GAPDH MFI for 
the positive, negative and blank controls (G POS, G NEG, G BLANK) as well as the mean MFI of the 
positive, negative and blank transcript controls of all four runs (T POS, T NEG, T BLANK). The boxes 
represent the 25th, 50th (median) and 75th percentiles of the signal distributions. The tails of the 
distributions are the whiskers – 1.5 times the interquartile range).  
 
The cut off values for a positive signal (350 MFI) and GAPDH signal (1000 MFI) are shown as dash 
lines. As expected, the GAPDH MFI of the blank control was well below the 1000 MFI cut-off 
recommended by the manufacturer while the negative control GAPDH was always greater than 
1000. In a single run, the positive control GAPDH signal was below 1000, but these results were 
included in the analysis. The negative and blank transcript controls were consistently less than 
350 MFI as required for acceptable analysis according to the manufacturer’s recommendations. 
Total number of 
samples 
n = 43
Concordant results
n = 41 (95.35%)
Discordant results
n = 2 (4.65%)
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Figure 3.5: Distribution of transcript positive, negative, blank and GAPDH endogenous control 
signals (MFI). 
(T POS – transcript positive control; T NEG – transcript negative control; T BLANK – transcript blank control; G POS – 
GAPDH positive control; G NEG – GAPDH negative control; G BLANK – GAPDH blank control; *** = p value < 0.001). 
Analysis of variance (ANOVA) testing showed a mean difference of 4041 MFI between the 
transcript positive MFI and transcript negative signal (P < 0.05) and 3928 MFI between the 
transcript positive control and transcript blank control signals (P < 0.05). No significant difference 
was shown between the transcript negative and transcript blank controls. A mean difference of 
3195 MFI (P < 0.05) and 4158 (P < 0.05) was shown between the GAPDH of the blank control and 
those of the positive and negative control GAPDH signals respectively (See Appendix 1).  
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The MFI signal for positive translocation results were > 1000 in all cases but two, which have 
already been described above as some of the discrepant results where the multiplex assay 
detected mutations which were not identified by FISH or cytogenetics. The median MFI for all 
positive transcripts was 3656. The median negative transcript MFI was 157.  
Figures 3.6 and 3.7 show all other mutations using cytogenetics or FISH in samples which were 
categorised as ‘Negative’ according to the translocations included in the Signature® LTx multiplex 
RT-PCR assay. The majority had normal karyotypes (35%), complex karyotypes (10%), partial 
deletions (13%) and hyperploidy (10%). FISH analysis also detected two cases of deletions 
involving chromosome five and two samples with deletions of chromosome seven (refer Figure 
3.6). 
 
Figure 3.6: Summary of mutations detected by cytogenetics which are not included in the 
multiplex assay 
35%
10%
10%
10%
10%
3%
3%
3%
3%
13%
Normal karyotype No metaphases Hyperploidy Complex karyotypes
trisomies t(7;15) t(6;9) i(17)
t(1;7) Deletions
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Figure 3.7: Summary of mutations detected by FISH analysis which are not included in the 
multiplex assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65%
23%
6%
6%
Negative Extra copies Abnormalities chromosome 5 Abnormalities chromosome 7
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4) Discussion 
As mentioned, leukaemia is a complex, heterogeneous disorder with numerous genetic 
abnormalities already identified as well as new potential aberrations which impact on diagnosis, 
treatment and prognostication.  As technology advances and the intricacies of this disease are 
further elucidated, the haematology laboratory should take advantage of these new methods in 
order to make the most accurate diagnosis as well as providing information to the treating 
oncologists within an acceptable time frame. This will not only be useful for prognostication 
purposes but also for potential targets for therapy. Although cytogenetic karyotyping remains the 
gold standard for diagnosis of acute leukaemias, other technologies especially those providing 
molecular diagnoses  should be embraced and used in conjunction with more traditional  
methods in order to make an accurate diagnosis, determine prognosis and tailor therapy to a 
specific molecular target. 
 
Several studies have investigated multiplex RT-PCR assays in the detection of leukaemia 
associated translocations and shown that it is a simple, rapid and sensitive testing method and   
possibly a valuable addition to the routine diagnostic testing of patients presenting with 
leukaemia [47, 49-52].  
 
The aim of our study was to evaluate the Signature® LTx Multiplex RT-PCR assay in the detection 
of leukaemia-associated translocations. We compared the results obtained using this assay with 
those of FISH and cytogenetics analysis which are part of the routine diagnostic work-up of 
patients presenting with leukaemia. 
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The study sample set demographics were determined by patient willingness to participate in the 
study, whether patients were able to consent and whether adequate diagnostic sample material 
could be collected at the initial bone marrow aspirate biopsy. However, these are all general 
exclusions and would not have affected one particular group of patients more than another e.g. 
children vs. adults. We collected fewer CML cases than those reflected in the NCR and CMJAH 
flow cytometry registries since these patients were often discharged soon after diagnosis and we 
were unable to collect peripheral blood if a sample was not taken at the time of the initial bone 
marrow aspirate biopsy. Sample collection was also influenced by the rapid turnover of interns 
and registrars in the Oncology units who were not always aware of the study and sample 
collection requirements.  
 
There were several limitations to our study including costing implications, the need for batching 
of samples, manual extraction problems and evaluation of the assay’s assessment of minimal 
residual disease.  
 
In terms of sample quality, it is noted that in the last run, all samples were less than 6 months old 
and a consistently improved RNA quality and concentration was observed (Table 3.3). Pre-
analytical factors could affect the quantity and quality of RNA. A limitation of this study was that 
we did not have any measures in place to assess the handling of PAXgene tubes e.g. volume of 
sample and temperature until they were received in the lab for processing and storage. If the 
Signature® LTx assay is to be implemented as part of the routine diagnostic investigation, there  
needs to be an emphasis on pre-analytical variables e.g. collection of only 2.5 mL of bone marrow 
aspirate/peripheral blood at the time of collection as well as maintaining appropriate 
temperature of PAXgene tubes during transport and storage.  
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Total RNA was initially isolated from peripheral blood or bone marrow specimens using the 
NucliSENS® easyMAG® (bioMerieux, Lyon, France). This however yielded suboptimal RNA quality 
and quantity and a manual extraction kit PAXgene Blood RNA Kit (PreAnalytix, Qiagen) was tested 
as an alternative. The manual extraction yielded better RNA concentrations (70 ng/µl) and 
qualities (1.8-2.2 A260/A280 ratio of sample absorbance), however some samples became viscous 
after the incubation step at 55°C.  This was noted in samples with a wide range of white cell 
counts and dates of collection with no obvious underlying cause. One of the greatest challenges 
faced in this study was discarding samples (n = 36) during the RNA extraction process as well as 
during RNA quantification owing to suboptimal quantity. Since our samples were batched before 
extraction, we could not assess whether this problem could be averted by extracting the samples 
upon arrival at the PCR laboratory. The A260:A280 ratio is not reflective of the integrity of the RNA. 
AS RNA is highly susceptible to degradation, it may influence the results and explain the low MFI 
values despite an adequate ratio. Troubleshooting would include comparing different RNA 
extraction methods in order to minimise discarding of samples or the need for more sample 
material to be sent by the requesting physician. Manual extraction also adds to the total time to 
obtain a result with an additional 4-5 hours required.  
 
The possible benefit of faster results and turnaround time may be hampered by the need to batch 
samples both for the assay and RNA extraction. Batching is required since all three controls need 
to be included, with only 24 samples per assay. If testing is done on fewer samples at a time e.g. 
as samples are received with immediate extraction and analysis, the full complement of 21 
samples will not be analysed per assay which will increase the cost per test and may not 
necessarily be more cost effective than individual FISH probes in order to achieve the improved 
turnaround times.  An example of how more frequent testing will impact on the cost per test is 
shown in Appendix 2.  
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In some runs, samples (n=10) were included despite not meeting the >70 ng/µl RNA 
concentration requirement. Of these ten samples, results correlated with gold standard methods 
results in 70% (7/10) of cases. The GAPDH signal was a problem in some cases, particularly in the 
third batch where the positive control GAPDH signal was less than 1000 MFI. According to the 
manufacturer’s recommendations, this result indicates that a re-run from the RT-PCR step is 
indicated, however for our purposes, these results were included in the analysis. Two thirds 
(14/21) of the samples in this run had GAPDH levels <1000 MFI, however of these, ten samples 
were concordant with the results reported by FISH and cytogenetics.  
  
In our study, all the concordant positive signals of the multiplex assay had MFI values of>1000 
MFI with a median signal intensity of 3656. There were two samples that had an MFI of <500. 
These samples (GA8, GP9) had mutations present which were not detected by either FISH or 
cytogenetics, and were therefore discordant. Statistically significant differences (P < 0.05) in the 
level of MFI readings were shown between transcript positive controls (T POS) and both transcript 
negative (T NEG) and blank controls (T BLANK) (Figure 3.5).  No statistically significant difference 
was found between the transcript negative (T NEG) and transcript blank controls (T BLANK). Both 
of these categories were well below the 350 MFI cut-off signal recommended by the 
manufacturer. These findings are as expected, as neither the transcript negative or blank controls 
contain any of the targeted mutations. The GAPDH signals were acceptable throughout all four 
batches for the positive (>1000 MFI), negative (>1000 MFI) and blank controls (<1000 MFI), with 
the exception of one batch where, the positive control GAPDH signal was <1000 MFI. The GAPDH 
signals were not statistically different in the positive and negative controls as expected. In the 
blank control, the GAPDH signal was consistently <1000 MFI with significantly lower MFI signals as 
compared to the positive (G POS) and negative (N POS) signals. 
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In a multicentre validation study of 280 patients, 95 % of true-positive signals (concordant 
positive results compared to FISH and cytogenetics) were double the 350 MFI cut-off and 
negative signals were significantly below the same cut-off value [39]. Calculations from the same  
study showed that 99.99% of probe signals would be below 343 MFI, equating to one potential 
false-positive signal for every 100 million reactions performed using true-negative samples 
(concordant negative results compared to FISH and cytogenetics) [39].The recommended MFI 
signal was therefore found to be an appropriate, even conservative cut-off value. 
 
The Signature® LTx multiplex assay showed good correlation with the gold standard diagnostic 
technique in our study with 10 (14.29 %) discordant results compared to 60 (85.71 %) concordant 
results. In these ten cases, there were some possible contributing factors identified e.g. RNA 
quantity, GAPDH MFI and fusion transcript MFI signal (Table 3.8).  
 
In the case of GA6, a patient with known AML with t(8;21)(q22:q22) RUNX1-RUNX1T1 who was 
receiving treatment had a repeat bone marrow biopsy, this translocation was identified using the 
Signature® LTx multiplex assay with a signal of 5814.0 MFI, however no FISH analysis was 
requested and the metaphases for cytogenetics were of poor quality.  The GAPDH signal was less 
than 1000 MFI. The mutation could not be confirmed by another method and the patient showed 
evidence of morphological and molecular remission in a bone marrow biopsy performed six 
months later. 
 
For the sample BP2, FISH analysis showed rearrangement of the MLL gene whereas cytogenetics 
identified a translocation involving chromosome eleven with an unknown fusion partner t(11;?). 
Therefore our multiplex assay result of t(4;11)(q21;q23)  is not necessarily a discordant result, but 
could not be confirmed using routine diagnostic tests. Nine of the ten discrepant results had 
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identifiable contributing factors and repeat testing may have yielded concordant results. 
However, in patient DP15, a diagnosis of APL was made at a referral hospital and the 
t(15;17)(q22;q12); PML-RARa was confirmed by cytogenetics at our centre. Despite adequate 
RNA quantity and GAPDH signal, the mutation was missed by the Signature® LTx assay with an 
MFI below 100 for both isoforms. 
 
If extraction were to be repeated with RNA concentration results <70ng/µl and PCR steps were 
repeated following a GAPDH results of < 1000 MFI, a total of 43 samples could be analysed, of 
which 95.35 % would be concordant and 4.65 % discordant compared to the FISH and 
cytogenetics reports. 
 
When discrepant results were identified by comparison to cytogenetics and FISH departments, 
we did not repeat analysis of these samples due to limited sample. Should this assay be 
implemented as part of the routine diagnostic investigations of patients presenting with 
leukaemia, appropriate flow diagrams need to be designed in the case of conflicting results.  The 
role in monitoring of minimal residual disease would form part of an ongoing assessment 
 
Alternative splicing isoforms or rare variants will not be detected with the Signature® LTx 
multiplex RT-PCR assay with a need for further specific primers to be added to the design; 
however the same challenge is faced in FISH analysis [39]. Multiplex assays are also not able to 
detect a complex karyotype, therefore they cannot be used in isolation and conventional 
cytogenetics remains the gold standard in investigation of patients with acute leukaemia.  
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We would recommended incorporation of more genetic abnormalities with prognostic 
significance including NPM1 (Nucleophosmin 1) and FLT3 (fms-related tyrosine kinase 3) in AML 
which both have significant prognostic implications [53]. The mutations 7q- and 5q- would be of 
value as well, particularly in the case of myelodysplasia as four of the cases in our patient set 
showed these abnormalities. In ALL, possible additions could include PAX5 (paired box protein 5) 
and IKZF1 (Ikaros family zinc finger protein 1) [34]. The addition of these mutations would be 
valuable because PAX5 mutation occurs in a third of B-cell ALL cases and IKZF1 mutations are 
identified in 15% of all paediatric B-ALL cases, more than 70% of BCR-ABL1 lymphoid leukaemia 
and in 10-15% of BCR-AB negative ALL [54]. It is associated with a poor prognosis [55]. Inclusion of 
both myeloid and lymphoid lineage translocations in one assay may be unnecessary in most cases  
following morphological, cytochemical or flow cytometry analysis, thereby necessitating 
development of disease-focused panels [39]. 
 
The multiplex panels were expanded in one multicentre validation study [39]. Two additional 
prototype panels were designed and tested, one focusing on t(9;22), t(12;21), t(4;11) and t(1;19) 
i.e. ALL-associated translocations. This assay could detect rare  t(12;21)(p13;q22); TEL-AML1 
(ETV6-RUNX1) e5e3 and t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) e13e2i27 variants as well as 
four additional MLL-AF1 variants. The second assay focused on AML-associated translocations 
and included added beads to detect CBFB-MYH11 type E and PML-RARa bcr2 variants as well as 
three most common NPM1 transcripts. These extended assays were found to have excellent 
correlation with cytogenetics and other molecular methods [39]. 
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5) Conclusion 
In our study, the Signature® LTx Multiplex RT-PCR assay showed good correlation with the gold 
standard of conventional cytogenetics as well as FISH analysis. In order to utilise the potential 
improved cost and turnaround time benefits of the assay, careful attention needs to be paid to 
pre-analytical variables, optimising the RNA extraction methods, possibly modifying the 
translocations included in the assay and having diagnostic algorithms in place particularly with 
regards to discordant results in order to incorporate its use within the routine diagnostic work-up 
of patients presenting with leukaemia. 
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Appendix 
 
Appendix 1: ANOVA testing of transcript positive, negative, blank and 
GAPDH endogenous control signals (MFI) 
 
Tukey's Multiple 
Comparison Test 
Mean 
Differenc
e 
q Significant? 
P < 0.05? 
Summar
y 
95% CI of 
difference 
T POS vs. T NEG 4041 30,20 Yes *** 3493 to 4589 
T POS vs T BLANK 3928 29,36 Yes *** 3380 to 4475 
T NEG vs T BLANK -113,0 0,844
9 
No ns -661.0 to 
434.9 
G POS vs G NEG -963,5 2,171 No ns -2781 to 
853.9 
G POS vs G BLANK 3195 7,199 Yes *** 1377 to 5012 
G NEG vs G BLANK 4158 9,370 Yes *** 2341 to 5975 
      
      
(T POS – transcript positive control; T NEG – transcript negative control; T BLANK – transcript blank control; G POS – 
GAPDH positive control; G NEG – GAPDH negative control; G BLANK – GAPDH blank control; *** = p value < 0.001; ns – 
not significant). 
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Appendix 2: Cost breakdown per test 
 
 
Reagents 
Cost/test (one 
batch per assay) 
Cost/test 
(two 
batches 
per 
assay) 
Cost/test 
(four 
batches 
per assay) 
PAXgene tubes R 110.00 R110.00 R110.00 
Extraction Cost R 252.04 R252.04 252.04 
Consumables:   
 
  Pipette tips R 5.83 R 5.83 R5.83 
Gloves R 1.54 R 1.54 1.54 
Eppendorf tubes R 10.45  R10.45 R10.45 
Signature LTx 
translocation Kit  
(including 
controls) 
R1795.50 2094.75 R 3142.13 
Co-star  96 well 
Plate 
R 26.32 R26.32 R26.32 
Sheath fluid R 18.73 R18.73 R18.73 
Costar 
Thermowell seals 
R 7.88 R7.88 R7.88 
  
  TOTAL: R2228.29 R2527.54 R3574.92 
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